BR112022017066A2 - Ácido nucleico antissentido indutor de salto do éxon 51 - Google Patents
Ácido nucleico antissentido indutor de salto do éxon 51Info
- Publication number
- BR112022017066A2 BR112022017066A2 BR112022017066A BR112022017066A BR112022017066A2 BR 112022017066 A2 BR112022017066 A2 BR 112022017066A2 BR 112022017066 A BR112022017066 A BR 112022017066A BR 112022017066 A BR112022017066 A BR 112022017066A BR 112022017066 A2 BR112022017066 A2 BR 112022017066A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- antisense nucleic
- exon skipping
- skipping
- exon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ÁCIDO NUCLEICO ANTISSENTIDO INDUTOR DE SALTO DO ÉXON 51. A presente especificação fornece um fármaco que causa salto altamente eficiente do éxon 51 no gene da distrofina humana. O presente relatório descritivo fornece um oligômero antissentido tendo atividade para induzir o salto do éxon 51 no gene da distrofina humana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020033483 | 2020-02-28 | ||
PCT/JP2021/007286 WO2021172498A1 (ja) | 2020-02-28 | 2021-02-26 | エクソン51のスキッピングを誘導するアンチセンス核酸 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022017066A2 true BR112022017066A2 (pt) | 2022-11-16 |
Family
ID=77491251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017066A BR112022017066A2 (pt) | 2020-02-28 | 2021-02-26 | Ácido nucleico antissentido indutor de salto do éxon 51 |
Country Status (17)
Country | Link |
---|---|
US (2) | US20230140736A1 (pt) |
EP (1) | EP4112083A1 (pt) |
JP (2) | JPWO2021172498A1 (pt) |
KR (1) | KR20220145865A (pt) |
CN (1) | CN115210376A (pt) |
AU (1) | AU2021226089A1 (pt) |
BR (1) | BR112022017066A2 (pt) |
CA (1) | CA3173049A1 (pt) |
CL (1) | CL2022002279A1 (pt) |
CO (1) | CO2022013685A2 (pt) |
EC (1) | ECSP22074446A (pt) |
IL (1) | IL295967A (pt) |
MX (1) | MX2022010545A (pt) |
PE (1) | PE20230237A1 (pt) |
TW (1) | TW202200162A (pt) |
WO (1) | WO2021172498A1 (pt) |
ZA (1) | ZA202209294B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
WO1991009033A1 (en) | 1989-12-20 | 1991-06-27 | Anti-Gene Development Group | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
JP2924179B2 (ja) | 1993-02-19 | 1999-07-26 | 日本新薬株式会社 | グリセロール誘導体,デバイス及び医薬組成物 |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
EP1568769A4 (en) | 2002-11-25 | 2008-08-06 | Masafumi Matsuo | ENA-NUCLEIC ACID MEDICAMENTS THAT CHANGE SPLICING IN THE MRNA PRESETTER |
WO2004083432A1 (en) | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
EP2206781B1 (en) | 2004-06-28 | 2015-12-02 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
SI2735568T1 (en) | 2006-05-10 | 2018-01-31 | Sarepta Therapeutics, Inc. | Analogues of the oligonucleotide, with cationic links between subunits |
WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
ES2639852T3 (es) | 2007-10-26 | 2017-10-30 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar los trastornos musculares |
RU2606627C2 (ru) | 2007-11-15 | 2017-01-10 | Серепта Терапьютикс,Инк. | Способ синтеза морфолиновых олигомеров |
BR122020021379B1 (pt) | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
SI2607484T1 (sl) | 2008-10-27 | 2016-11-30 | Biomarin Technologies B.V. | Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije |
TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
KR102339196B1 (ko) | 2011-05-05 | 2021-12-15 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
CN112251436A (zh) | 2012-01-27 | 2021-01-22 | 比奥马林技术公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
JP6519842B2 (ja) | 2013-10-04 | 2019-05-29 | 国立大学法人神戸大学 | 福山型筋ジストロフィー治療用アンチセンス核酸 |
LT3118311T (lt) | 2014-03-12 | 2019-04-10 | Nippon Shinyaku Co., Ltd. | Priešprasminė nukleorūgštis |
US10675356B2 (en) | 2015-05-19 | 2020-06-09 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
SI3331891T1 (sl) | 2015-08-05 | 2022-04-29 | Eisai R&D Management Co., Ltd. | Postopek priprave v bistvu diastereomerno čistega fosforodiamidatnega oligomera, fosforodiamidatni oligomer izdelan po takem postopku in farmacevtski sestavek, ki vsebuje tak fosforodiamidatni oligomer |
TW201722439A (zh) | 2015-10-09 | 2017-07-01 | 波濤生命科學有限公司 | 寡核苷酸組合物及其方法 |
EP3485015A4 (en) * | 2016-07-15 | 2020-07-29 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS OF MODULATION OF DYSTROPHINE TRANSCRIPT |
WO2018118599A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
LT3554552T (lt) | 2016-12-19 | 2022-10-10 | Sarepta Therapeutics, Inc. | Egzoną praleidžiantys oligomerų konjugatai nuo raumenų distrofijos |
CN117298290A (zh) | 2016-12-19 | 2023-12-29 | 萨勒普塔医疗公司 | 用于肌肉萎缩症的外显子跳跃寡聚体缀合物 |
WO2019241385A2 (en) | 2018-06-13 | 2019-12-19 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystropy |
-
2021
- 2021-02-26 IL IL295967A patent/IL295967A/en unknown
- 2021-02-26 CN CN202180017313.6A patent/CN115210376A/zh active Pending
- 2021-02-26 WO PCT/JP2021/007286 patent/WO2021172498A1/ja active Application Filing
- 2021-02-26 EP EP21760603.7A patent/EP4112083A1/en active Pending
- 2021-02-26 MX MX2022010545A patent/MX2022010545A/es unknown
- 2021-02-26 AU AU2021226089A patent/AU2021226089A1/en active Pending
- 2021-02-26 PE PE2022001832A patent/PE20230237A1/es unknown
- 2021-02-26 BR BR112022017066A patent/BR112022017066A2/pt unknown
- 2021-02-26 US US17/802,720 patent/US20230140736A1/en active Pending
- 2021-02-26 CA CA3173049A patent/CA3173049A1/en active Pending
- 2021-02-26 KR KR1020227032708A patent/KR20220145865A/ko unknown
- 2021-02-26 JP JP2022503739A patent/JPWO2021172498A1/ja active Pending
- 2021-02-26 TW TW110107021A patent/TW202200162A/zh unknown
-
2022
- 2022-08-18 ZA ZA2022/09294A patent/ZA202209294B/en unknown
- 2022-08-22 CL CL2022002279A patent/CL2022002279A1/es unknown
- 2022-08-25 US US17/895,186 patent/US11781140B2/en active Active
- 2022-09-06 JP JP2022141656A patent/JP7292636B2/ja active Active
- 2022-09-23 EC ECSENADI202274446A patent/ECSP22074446A/es unknown
- 2022-09-23 CO CONC2022/0013685A patent/CO2022013685A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3173049A1 (en) | 2021-09-02 |
CO2022013685A2 (es) | 2022-10-11 |
TW202200162A (zh) | 2022-01-01 |
ECSP22074446A (es) | 2022-10-31 |
PE20230237A1 (es) | 2023-02-07 |
KR20220145865A (ko) | 2022-10-31 |
WO2021172498A1 (ja) | 2021-09-02 |
JP7292636B2 (ja) | 2023-06-19 |
US20230140736A1 (en) | 2023-05-04 |
JP2022180420A (ja) | 2022-12-06 |
ZA202209294B (en) | 2024-04-24 |
US20230097387A1 (en) | 2023-03-30 |
AU2021226089A1 (en) | 2022-09-15 |
EP4112083A1 (en) | 2023-01-04 |
US11781140B2 (en) | 2023-10-10 |
IL295967A (en) | 2022-10-01 |
CN115210376A (zh) | 2022-10-18 |
JPWO2021172498A1 (pt) | 2021-09-02 |
CL2022002279A1 (es) | 2023-02-10 |
MX2022010545A (es) | 2022-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002585A1 (es) | Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central | |
Tammen et al. | Epigenetics: the link between nature and nurture | |
Kofink et al. | Epigenetic dynamics in psychiatric disorders: environmental programming of neurodevelopmental processes | |
Barthas et al. | Cingulate overexpression of mitogen-activated protein kinase phosphatase-1 as a key factor for depression | |
Maity et al. | Epigenetic mechanisms in memory and cognitive decline associated with aging and Alzheimer’s disease | |
Kenworthy et al. | Social defeat induces changes in histone acetylation and expression of histone modifying enzymes in the ventral hippocampus, prefrontal cortex, and dorsal raphe nucleus | |
BR112015005862A2 (pt) | derivados de hidropirrolpirrol para uso como inibidores de ácido graxo sintase | |
AR049504A1 (es) | Polinucleotidos de proteinas asociadas con la resistencia a multiples drogas en maiz y metodos para usarlos | |
Davinelli et al. | Epigenetic nutraceutical diets in Alzheimer's disease | |
BR112018067442A8 (pt) | Composto, composição farmacêutica, método de inibir a atividade da amina oxidase, método de tratar uma condição e uso de um composto | |
Krause et al. | Conceptos generales de epigenética: proyecciones en pediatría | |
DOP2006000205A (es) | Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion y su uso como productos farmaceuticos. | |
BR112022017066A2 (pt) | Ácido nucleico antissentido indutor de salto do éxon 51 | |
CL2021001490A1 (es) | Constructos de iarn modificados químicamente y usos de estos | |
UY30762A1 (es) | Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol | |
UY28976A1 (es) | Uso de benzopiranonas trisustituidas | |
GT200600463A (es) | Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas | |
Beiter et al. | Transcriptional memory in skeletal muscle. Don't forget (to) exercise | |
CO2020006361A2 (es) | Tratamiento antisentido del síndrome de angelman | |
BR112023000428A2 (pt) | Métodos e composições para tratar epilepsia | |
Abdolmaleky et al. | Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics | |
BR112015029619A2 (pt) | derivados de 1,3-diaminociclopentano carboxamida | |
BRPI0414822A (pt) | método de inibir a produção de lipoproteìna remanescente | |
BR112021021686A2 (pt) | Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas | |
CO2022008664A2 (es) | Ácido nucleico antisentido que induce la omisión del exón 50 |